Video

Dr. Gomella on Surrogate Endpoints in Prostate Cancer

Leonard G. Gomella, MD, from the Thomas Jefferson University Hospital, describes the identification of appropriate surrogate endpoints for the evaluation of new therapies for patients with metastatic castration-resistant prostate cancer.

Leonard G. Gomella, MD, professor and chair of the Department of Urology at Thomas Jefferson University Hospital, describes the need to identify appropriate surrogate endpoints for the evaluation of new treatments and combination strategies in metastatic castration-resistant prostate cancer (mCRPC).

Some of the challenges facing mCRPC researchers revolve around the currently accepted endpoints used in clinical trials, Gomella notes. In some cases, PSA is an effective endpoint. However, newer endpoints, such as radiographic progression-free survival and RECIST criteria, may also be considered and should be explored more thoroughly, Gomella believes.

In general, overall survival is still the major endpoint needed for regulatory approval of new medications in mCRPC. In addition to OS, quality of life measurements are an important endpoint to consider. As more targeted and novel agents are developed, the focus on identifying and validating surrogate endpoints will continue to increase, Gomella believes.

<<<

View coverage from the 2013 IPCC

Related Videos
Lajos Pusztai, MD, DPhil
Hope S. Rugo, MD
Alicia Morgans, MD, MPH, genitourinary medical oncologist, medical director, Survivorship Program, Dana-Farber Cancer Institute; associate professor, medicine, Harvard Medical School
Stephen J. Freedland, MD, and Eleni Efstathiou, MD, PhD, experts on prostate cancer
Stephen J. Freedland, MD, and Eleni Efstathiou, MD, PhD, experts on prostate cancer
Jun Gong, MD, associate professor, medicine, medical oncologist, Gastrointestinal Disease Research Group, Pancreatic Cancer Research Group, Urologic Oncology Program, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai
Karl Semaan, MD, MSc
Bradley McGregor, MD, discusses findings from a phase 1b study of abemaciclib  in clear cell renal cell carcinoma.
Marc-Oliver Grimm, MD
Toni K. Choueiri, MD